MFDS
- Marketing authorisation holder: CHECKPOINT THERAPEUTICS INC
- Status: likely_approved
🇰🇷 Unloxcyt in South Korea
Unloxcyt (COSIBELIMAB) regulatory status in South Korea.
Marketing authorisation
Unloxcyt in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in South Korea
Frequently asked questions
Is Unloxcyt approved in South Korea?
Yes. MFDS has authorised it.
Who is the marketing authorisation holder for Unloxcyt in South Korea?
CHECKPOINT THERAPEUTICS INC holds the South Korean marketing authorisation.